Expression of adhesion receptor integrin ␣v␤3 in an activated functional form strongly promotes metastasis in human breast cancer cells. Here, we report that ␣v␤3 cooperates with matrix metalloproteinase type 9 (MMP-9) in breast cancer cell migration. This cooperation is regulated by the activation state of the integrin. Expression of activated ␣v␤3 in metastatic variants of MDA-MB 435 human breast cancer cells and primary metastatic cells from breast cancer patients strongly enhanced migration toward vitronectin and fibrinogen. This enhancement was mediated by a soluble factor produced by breast cancer cells expressing activated ␣v␤3. When transferred, this factor also up-regulated ␣v␤3-dependent migration of breast cancer cells that express the nonactivated integrin. The factor was identified as metalloproteinase MMP-9. Whereas all tested breast cancer cell variants produced latent MMP-9, only those with activated ␣v␤3 produced the mature form of this metalloproteinase. Recombinant mature MMP-9, but not latent MMP-9 or either form of MMP-2, enhanced ␣v␤3-dependent breast cancer cell migration. The migratory response was inhibited by tissue inhibitors of metalloproteinase or when MMP-9 was depleted from the inducing supernatants. The results indicate a causal relationship between the expression of activated integrin ␣v␤3 and production of enzymatically active MMP-9 in metastatic breast cancer cells. These molecules cooperate to enhance breast cancer cell migration toward specific matrix proteins, and this may contribute to the strongly enhanced metastatic capacity of breast cancer cells that express activated ␣v␤3.
M
etastasis is the primary cause of death in breast cancer patients. Metastatic dissemination depends on tumor cell adhesion, migration, and invasion. These steps involve integrins, a family of transmembrane adhesion receptors, composed of noncovalently linked ␣ and ␤ subunits (1) . Integrins are known to exist in distinct states of activation, and these determine integrin functionality and affinity for ligands (2) . For example, integrin activation controls which ligands are recognized, whether an integrin can support cell arrest under dynamic flow conditions or only stationary adhesion, and whether cells can migrate on or toward specific substrates (3) . The importance of integrin activation has long been appreciated in leukocytes and platelets, where it controls inflammatory responses and thrombus formation (4, 5) . Recent findings indicate that other cell types, such as endothelial cells and tumor cells, can also regulate their interaction with extracellular matrix proteins by integrin activation (6) (7) (8) (9) . This regulation may help to control angiogenesis and tumor metastasis.
In breast and ovarian cancer, as well as in melanoma and glioma, malignant progression is associated with expression of tumor cell integrin ␣v␤3 (10) (11) (12) (13) (14) . We recently found that ␣v␤3 can exist in human breast cancer cells in an activated or a nonactivated functional state. Only the activated state supports breast cancer cell arrest during blood flow, as in the circulation. Importantly, activated but not nonactivated ␣v␤3 strongly promotes breast cancer metastasis (9, 15) . Whereas tumor cell arrest in flowing blood may be critical during hematogenous metastasis, metastatic dissemination also depends on the control of tumor cell motility. Changes in migratory functions can be induced by growth factors and altered production and activity of matrix-degrading enzymes, such as metalloproteinases. Connections between these phenomena and integrin function are just beginning to emerge (3, (16) (17) (18) . Here, we asked whether and how the activation state of tumor cell integrin ␣v␤3 helps to regulate breast cancer cell migration. Our results show that ␣v␤3 activation strongly enhances breast cancer migration toward specific substrates and that this process depends on a cooperation between the integrin and matrix metalloproteinase type 9 (MMP-9) in an activation-dependent pathway. We thereby establish a mechanism by which the activation state of integrin ␣v␤3 can contribute to migratory responses of metastatic breast cancer cells.
Methods
Cells. MDA-MB 435 human breast cancer cells were from J. E. Price (M. D. Anderson Cancer Center, Houston). These cells (parent) were injected into the mammary fat pad of immunedeficient mice, and metastatic variants were selected from metastases to bone or lung (9) . A ␤3 integrin negative variant (␤3 minus ) was selected in vitro after treating MDA-MB 435 parent cells with an anti-␤3-saporin conjugate (9) . The ␤3-negative variant was stably transfected either with ␤3 wild type (␤3 WT ) or with constitutively activated mutant ␤3 (␤3 D723R ) (9) . Primary metastatic human breast cancer cells were isolated from a pleural effusion (PEO2JA) (9) or from peripheral blood samples (BCM1, BCM2, and BMS) of stage IV breast cancer patients by immunomagnetic bead sorting with antiepithelial antibody BerEP4 (Dynal, Great Neck, NY). The patient-derived cells express integrin ␣v␤3 at levels comparable to those of the MDA-MB 435 cell variants. The cells further express EpCAM, an epithelial marker, and mammaglobin.
Migration. Haptotactic breast cancer cell migration toward purified extracellular matrix proteins was analyzed in transwells (8-m pore size; Costar). Filter undersides (triplicates) were coated with human vitronectin (10 g͞ml), fibrinogen (plasminogen free) (20 g͞ml), von Willebrand factor (5 g͞ml), or BSA in PBS and blocked with 2.5% BSA in 0.2% Tween 20͞PBS. Cells were starved overnight in serum-free medium (Eagle's minimal essential medium, EMEM), harvested with PBS͞ EDTA, washed, and seeded at 3 ϫ 10 and centrifuged before use. Inhibitors were added to cells immediately before the migration assay and left in place for the duration of the test [function blocking anti-␤3 integrin mAb 7E3 at 80 g͞ml, tissue inhibitors of metalloproteinase-1 (TIMP-1) at 1 g͞ml, TIMP-2 at 3.75 g͞ml]. Latent or mature recombinant human MMP-2 or MMP-9 (Oncogene; 40 ng͞ml) were added to serum-free EMEM migration medium or were used at this concentration to preincubate cells or matrix proteins as soluble of immobilized substrates before use in migration assays. Pairwise differences were evaluated by standard analyses of variance followed by multiple comparisons (Scheffé's method).
Zymography. Metalloproteinase activity in supernatants was tested by zymography. Conditioned media were harvested from 48-h cultures in serum-free EMEM, and proteins were precipitated at 56% (NH 4 ) 2 SO 4 overnight at 4°C, pelleted at 19,000 ϫ g, and dialyzed against TBS containing 0.0005% Brij35. Protein concentrations were determined by MicroBCA (Pierce). Twenty-five micrograms of total protein were analyzed under nonreducing conditions on 8% polyacrylamide gels containing either 0.05% gelatin or 0.005% human fibrinogen. For development, gels were washed three times in 2.5% Triton X-100, incubated overnight at 37°C in 40 mM Tris͞200 mM NaCl͞10 mM CaCl 2 (pH 7.5), and stained with Coomassie blue.
Immunodepletion. MMP-9 was depleted from conditioned breast cancer cell supernatants or EMEM containing 40 ng͞ml human recombinant mature MMP-9 by three rounds of incubation (45 min each at 22°C) with protein A-Sepharose beads (Repligen) carrying rabbit anti-mouse IgG (Zymed) and monoclonal murine anti-human MMP-9 antibody (Oncogene Ab-7). Control supernatants were incubated three times with protein-A antimouse beads without anti-MMP-9.
Results

Activated Integrin ␣v␤3 Enhances Matrix-Directed Breast Cancer Cell
Migration. Expression of integrin ␣v␤3 in a constitutively activated functional form strongly enhances metastasis of human breast cancer cells (9) . To analyze mechanisms through which the activated receptor may support metastatic dissemination, we compared the migratory activities of human breast cancer cell variants that stably express ␣v␤3 either in an activated or a nonactivated functional form. The MDA-MB 435 parental cell population at large expresses nonactivated ␣v␤3, whereas its in vivo-selected, metastasis-derived variants express activated ␣v␤3 (9). These cells were compared with an in vitro selected ␤3-lacking MDA-MB 435 variant (␤3 minus ) or its transfectants that express either nonactivated ␣v␤3 (␤3 WT ) or constitutively activated mutant ␤3 (␤3 D723R ). Breast cancer cell variants with activated ␣v␤3 showed enhanced migration toward vitronectin and fibrinogen (Fig. 1A) . This finding has clinical relevance because primary metastatic cells from stage IV breast cancer patients, isolated either from a pleural effusion (PE02JA) or from peripheral blood samples (BCM1, BCM2, and BMS) express activated ␣v␤3 ( Table 1 ). The activated receptor supports platelet-mediated tumor cell arrest during blood flow (9) and mediated enhanced migration toward vitronectin and fibrinogen compared with MDA-MB 435 parental cells, which express ␣v␤3 at a similar level but in a nonactivated functional form (Fig. 1B) . Whereas vitronectin-directed migration was supported by ␣v␤3 plus other ␣v integrins, fibrinogen-directed migration depended on ␣v␤3, as it was strongly inhibited by a function blocking anti-␤3 antibody (Fig. 1C) . Thus, migration of metastatic breast cancer cells toward fibrinogen is mediated by integrin ␣v␤3, and it is very strongly enhanced if the receptor is activated. Exogenous integrin activation of MDA-MB 435 parental cells with Mn 2ϩ did not significantly enhance migration (Fig. 1D) . This indicates that breast cancer cell migration depends on the endogenous control of ␣v␤3 functionality and perhaps on other supporting factors.
Breast Cancer Cells with Activated ␣v␤3 Produce a Migration-Stimulating Factor. To probe for potential factors that are produced by activated ␣v␤3 expressing breast cancer cells and modify their migration, we analyzed conditioned supernatants of these cells. Supernatants of MDA-MB 435 bone cells and the ␤3 D723R expressing variant, as well as patient-derived metastatic breast cancer cells, induced fibrinogen-directed migration of MDA-MB 435 parental cells ( Fig. 2A ). This was mediated by integrin ␣v␤3 of the responding cells (Fig. 2B ). Conditioned supernatants of the in vivo selected metastatic cell variant (bone) and primary metastatic cells from breast cancer patients (BCM2) did not further increase their own robust fibrinogen-directed migration, but supernatants of the in vitro generated MDA-MB 435 variant ␤3 D723R maximized the migratory response in these cells (Fig.  2 A) . Importantly, supernatants of ␤3 D723R -expressing cells or primary metastatic breast cancer cells induced fibrinogendirected migration in the ␤3 WT -expressing cell variant, but not in ␤3 minus cells (Fig. 2 A) . The promigratory effect was specific for the haptotactic substrate, because it was seen on fibrinogen and to a lesser extent on fibronectin, but not on vitronectin. Conditioned supernatants of MDA-MB 435 parental cells or their ␤3 minus -or ␤3 WT -expressing variants did not stimulate fibrinogen-directed migration (Fig. 2 A) . This indicates that only breast cancer cells with activated ␣v␤3 produce and release a soluble factor(s), which stimulates ␣v␤3-mediated, substrate-specific migration in breast cancer cells, even if they per se express the nonactivated receptor.
Breast Cancer Cells with Activated ␣v␤3 Produce the Mature Form of
Metalloproteinase MMP-9. Compounds known to alter tumor cell migration are the metalloproteinases (19) . Therefore, we analyzed metalloproteinases in conditioned supernatants of breast cancer cell variants that express either activated or nonactivated ␣v␤3. All tested variants of the MDA-MB 435 breast cancer cell line produced a gelatinase with an apparent molecular mass of 92 kDa (Fig. 3A) . This is consistent with characteristics of latent metalloproteinase MMP-9 (proMMP-9). The presence of MMP-9 was confirmed by Western analysis (Fig. 3C) . Interestingly, an 82-kDa gelatinase consistent with mature MMP-9 was detected only in supernatants of breast cancer cells that express activated ␣v␤3 (MDA-MB 435 lung and ␤3 D723R shown in Fig.  3A on a gelatin zymogram, and BCM1, BCM2, and BMS shown in Fig. 3B on a fibrinogen zymogram) . In addition, all breast cancer cell variants produced a 72-kDa gelatinase, most likely MMP-2, regardless of their ␣v␤3 activation state. The presence of MMP-2 was confirmed by Western analysis. Thus, both groups of breast cancer cells, those with activated and those with nonactivated integrin ␣v␤3, produce proMMP-2 and proMMP-9. However, production of mature MMP-9 seems to be restricted to cells expressing activated ␣v␤3. Thus, enhanced ␣v␤3-dependent breast cancer cell migration toward fibrinogen coincides with the ability of the cells to generate a metalloproteinase with characteristics of mature MMP-9.
MMP-9 may affect fibrinogen-directed breast cancer cell migration by modifying the substrate and converting it into a promigratory format (20) (21) (22) . The 82-kDa metalloproteinase produced by breast cancer cells expressing activated ␣v␤3 degraded fibrinogen, as shown by zymography (Fig. 3B ). This indicates that breast cancer cells with activated ␣v␤3, but not those with nonactivated ␣v␤3, produce a metalloproteinase whose apparent molecular weight, substrate specificity, and immunologic reactivity match that of mature MMP-9. The mature enzyme may enhance fibrinogen-directed tumor cell migration.
MMP-9
Stimulates ␣v␤3-Dependent Breast Cancer Cell Migration. The production of mature MMP-9 was found restricted to breast cancer cells with activated ␣v␤3, and only supernatants of these cells promoted ␣v␤3-dependent migration. To test directly whether mature MMP-9 is responsible for this effect, we analyzed whether the effect was inhibited by MMP antagonists, (9, 46) . Parent, bone, and the ␤3 variants are derivatives of the MDA-MB 435 cell line. BCM1, BCM2, and BMS are primary metastatic cells isolated from blood samples of stage IV breast cancer patients. , their metastasis-derived variant (Lung), or the in vitro generated variants that lack ␤3 integrin (␤3minus) or express either activated mutant ␤D723R or nonactivated ␤3WT. BCM1, BCM2, and BMS are patient-derived primary metastatic cells. Twenty-five micrograms of total protein were separated on polyacrylamide gels (8%) containing 0.05% gelatin (A) or 0.005% human fibrinogen (B) (nonreducing). (C) Detection of MMP-9 in breast cancer cell supernatants and Western blot analysis of concentrated spent supernatants after SDS͞PAGE (8%) separation under nonreducing (Left) or reducing (Right) conditions. Reactivity is shown with anti-MMP-9 (oncogene mAb-7). The nonreduced 240-kDa bands were also positive with anti-TIMP-1 (oncogene mAb-1), consistent with an MMP-9͞TIMP-1 complex dimer.
mimicked by recombinant mature MMP-9, and reversed by depleting MMP-9 from the supernatants.
To test whether MMP antagonists block the promigratory effect of supernatants from activated ␣v␤3-expressing breast cancer cells, MDA-MB 435 parental cells were allowed to migrate toward fibrinogen in conditioned supernatants of MDA-MB 435 bone or BCM2 cells, in the presence or absence of TIMP. The promigratory effect of the supernatants was abolished by TIMP-1 (1 g͞ml, Fig. 4 A and B) and reduced by TIMP-2 (3.75 g͞ml, Fig. 4C ). This indicates that a metalloproteinase stimulates ␣v␤3-dependent, substrate-specific breast cancer cell migration. Importantly, this metalloproteinase is produced by metastatic breast cancer cells with activated ␣v␤3 and maximizes their ␣v␤3-mediated migration.
To analyze whether MMP-9 can stimulate ␣v␤3-mediated breast cancer cell migration toward fibrinogen, MDA-MB 435 parental cells were allowed to migrate in plain medium supplemented with recombinant mature MMP-9, compared with proMMP-9 or either form of MMP-2. Whereas MMP-2 and proMMP-9 had no effect, mature MMP-9 increased migration of the parental cells to levels seen in conditioned supernatants of the bone metastasis-derived cell variant (Fig. 4D) . Thus, purified mature MMP-9 and supernatants produced by activated ␣v␤3-expressing breast cancer cells have similar effects. Both stimulated ␣v␤3-dependent breast cancer cell migration. To prove that MMP-9 is indeed the active component in conditioned supernatants of metastatic breast cancer cells that maximizes fibrinogen-directed migration, MMP-9 was depleted from these supernatants. The promigratory effects of supernatants from breast cancer cells with activated ␣v␤3 (MDA-MB 435 bone or ␤3 D723R and BCM2) were strongly decreased when MMP-9 was removed from the supernatants. Similarly, depletion of MMP-9 from MMP-9-spiked medium reversed the promigratory effect (Fig. 5A) . Control treatment of conditioned supernatants with protein-A anti-mouse beads without anti-MMP-9 did not compromise the promigratory effect (Fig. 5A) . Therefore, the mature form of MMP-9, produced by metastatic breast cancer cells, maximizes ␣v␤3-dependent breast cancer cell migration toward a fibrinogen substrate. The promigratory effect of MMP-9 was also observed when ␣v␤3-positive breast cancer cells were pretreated with mature MMP-9 and washed before the migration assay (Fig. 5B) . Treatment of ␤3-lacking breast cancer cells had no effect, as did treatment of either cell variant with MMP-2. Thus, MMP-9 can enhance ␣v␤3-mediated breast cancer cell (3), or MMP-9 spiked medium (4) compared with controltreated medium containing MMP-9 (5). (B) Recombinant MMP-9 enhances migration of ␣v␤3-positive breast cancer cells. Fibrinogen-directed migration of MDA-MB 435 cell variants expressing ␤3WT or constitutively activated mutant ␤3D723R, or which lack ␤3 (␤3minus), pretreated for 2 h with medium (white) or medium plus 40 ng͞ml recombinant mature MMP-2 (gray) or MMP-9 (black) and washed before the migration assay. *, P Ͻ 0.05, significantly greater than both other conditions for these cell types. (C and D) MMP-9-digested fibrinogen is strongly haptotactic. (C) Digestion of a fibrinogen matrix. MDA-MB 435 parent cell migration toward modified fibrinogen matrices. Undersides of transwell filters were coated with 20 g͞ml fibrinogen, BSA blocked, and then placed in fresh lower wells with plain medium and exposed to spent supernatants from MDA-MB 435 bone or BCM2 cells, or to medium containing 40 ng͞ml recombinant mature MMP-9 in the upper well for 4 h at 37°C. Before adding cells, upper wells were washed, and the liquid in the lower wells was replaced by fresh plain medium (gray) or kept in place (black). (D) Digestion of soluble fibrinogen. MDA-MB 435 parent cell migration toward digested fibrinogen is shown. Soluble fibrinogen (20 g͞ml) was digested with spent supernatant of BCM2 cells or with 40 ng͞ml recombinant mature MMP-9 for 4 h at 37°C, then treated three times either with protein A anti-mouse beads (gray) or protein A anti-mouse͞anti-MMP-9 to deplete MMP-9 (black), before coating transwell filters with the digested material. (E) Delayed migration toward von Willebrand factor, which was digested with MMP-9 for 13 h at 37°C, then coated to filters and blocked; BCM2 cells were then allowed to migrate in EMEM for up to 48 h. migration toward fibrinogen through modification of the cell surface. In addition, MMP-9 produced by breast cancer cells expressing activated ␣v␤3 can degrade fibrinogen (Fig. 3B) and may convert it into a promigratory format. To test this, immobilized or soluble fibrinogen was digested with spent supernatants of breast cancer cells expressing activated ␣v␤3 (MDA-MB 435 bone or BCM2) or with recombinant mature MMP-9. Digestion of fibrinogen matrices (Fig. 5C ) or soluble fibrinogen (Fig. 5D ) enhanced migration of breast cancer cells that express nonactivated ␣v␤3 (MDA-MB 435 parent), especially when the fibrinogen degradation products remained in the lower transwell or were coated to the underside of the filters. This was observed with and without depletion of MMP-9 from the digests (Fig. 5D) . Prolonged exposure of von Willebrand factor to MMP-9 or breast cancer cells, which express activated ␣v␤3 and release mature MMP-9, eventually triggered some migration. The delay in the migratory response may be caused by the complex and highly multimeric nature of this substrate (Fig. 5E) .
Together, breast cancer cells expressing activated integrin ␣v␤3 are highly metastatic and migrate much more actively toward certain matrix proteins than their nonactivated ␣v␤3-expressing counterparts. The enhanced migration is mediated through a cooperation between integrin ␣v␤3 and the mature form of metalloproteinase MMP-9. Expression of activated ␣v␤3 and production of mature MMP-9 coincide in metastatic breast cancer cells and maximize ␣v␤3-mediated migration in a substrate-specific manner.
Discussion
Breast cancer cells can express the adhesion receptor integrin ␣v␤3 in an activated or a nonactivated functional form. Expression of activated ␣v␤3 promotes tumor cell arrest during blood flow and causes a drastic increase in metastatic activity (9, 15, 23) . Integrin activation modulates ligand recognition, cell migration, and invasion (6, 7, (24) (25) (26) and endows tumor cells with crucial functions that permit or facilitate a disseminating phenotype. Here, we analyzed consequences of ␣v␤3 activation on breast cancer cell motility, an important function during metastasis. We show that intrinsic ␣v␤3 activation strongly increased breast cancer cell migration, involving a mechanism where ␣v␤3 cooperates with metalloproteinase MMP-9 to maximize tumor cell motility.
To analyze specific contributions of activated versus nonactivated integrin ␣v␤3, we chose a cell model based on MDA-MB 435 human breast cancer cells. In vivo selected metastatic variants of this cell line express activated ␣v␤3 (9). This was recapitulated in vitro by transfecting a ␤3 minus variant of these cells with constitutively activating mutant ␤3 D723R , which caused a drastic increase in metastatic activity compared with ␤3 WT (9) . To analyze a clinical significance of ␣v␤3 activation, we established primary metastatic cells from blood samples of stage IV breast cancer patients. These cells express integrin ␣v␤3 in an activated functional form as the receptor supports tumor cell arrest during blood flow (9, 23) . In these cell models, ␣v␤3 activation caused enhanced breast cancer cell migration toward fibronectin (9), vitronectin, and fibrinogen. Integrin activation may alter ligand specificity and induce migration on or toward matrix proteins that are not recognized as migratory substrates by the nonactivated receptors (6, 24, 27, 28) . Vitronectin and fibronectin are recognized by breast cancer cell integrin ␣v␤3 plus other ␣v and ␤1 integrins, whereas fibrinogen is recognized by ␣v␤3 only. Migration toward fibrinogen was poor in breast cancer cells with nonactivated ␣v␤3 but very strong in cells with activated ␣v␤3. Therefore, we focused on fibrinogen to analyze how breast cancer cell motility is affected by ␣v␤3 activation.
We found that breast cancer cells can up-regulate ␣v␤3-mediated migration through cooperation of ␣v␤3 with metalloproteinase MMP-9 in an activation-dependent pathway. Expression and ligation of ␣v␤3 and other integrins can stimulate MMP-9 production and function (29) (30) (31) . However, we show that the presence of ␣v␤3 is not sufficient to up-regulate MMP-9 functionality, but that this is regulated by the activation state of the integrin. In our breast cancer cell model, all tested variants produced proMMP-9, but only cells expressing activated ␣v␤3 released a metalloproteinase with characteristics of mature MMP-9. This compound up-regulated ␣v␤3-mediated migration of breast cancer cells very strongly, even if these per se express nonactivated ␣v␤3 (cis-and trans-activation). The promigratory factor in supernatants of breast cancer cells with activated ␣v␤3 was identified as mature MMP-9 by its apparent molecular weight, substrate specificity, inhibition by its natural inhibitors, and immunoreactivity͞depletion with monoclonal antibodies. Expression of activated ␣v␤3 and release of mature MMP-9 coincided in the in vivo selected metastatic MDA-MB 435 cell variants and in patient-derived metastatic breast cancer cells. The finding that the in vitro generated MDA-MB 435 variant ␤3 D7223R also produced mature MMP-9 implies a causal relationship between ␣v␤3 activation and MMP-9 maturation. These cells were generated by transfecting MDA-MB 435 ␤3 minus cells with ␤3 D723R , which carries a mutation in the cytoplasmic ␤3 hinge region and renders ␣v␤3 constitutively active (32, 33) . ␤3 D723R -expressing cells are highly metastatic, produce mature MMP-9, and migrate actively toward fibrinogen. Transfection of MDA-MB 435 ␤3 minus cells with ␤3 WT , instead of ␤3 D723R , resulted in a variant that expresses nonactivated ␣v␤3, metastasizes very poorly (9), does not produce mature MMP-9, and largely fails to migrate toward fibrinogen. Thus, in this cell model, MMP-9 maturation and its consequences for cell migration seem to be directly linked to the activation state of integrin ␣v␤3.
A mechanism by which activated integrin ␣v␤3 may contribute to MMP-9 maturation is not known. MMPs are secreted by stromal or tumor cells as inactive pro-enzymes and must bind to the cell surface, where they are processed and activated (34) . For MMP-2, this is mediated by an MT1-MMP͞TIMP-2͞MMP-2 ternary complex or an alternative protein C-dependent pathway (34, 35) . It may involve integrin ␣v␤3 on sprouting endothelial cells, where ␣v␤3 recognizes the C-terminal hemopexin homology domain of MMP-2 (36) and colocalizes with MMP-2 at the invasive cell front (34) . Disrupting ␣v␤3͞MMP-2 binding inhibits angiogenesis (36) (37) (38) . A mechanism for MMP-9 activation at the cell surface has yet to be established. Cell-surface molecules known to bind MMP-9 are the ␣2(IV) chain of collagen IV (39) and the hyaluronan receptor CD44 (40) . Our results indicate that tumor cell ␣v␤3 could be involved in MMP-9 processing and targeting the enzyme to cell-matrix contacts. Human MMP-9 contains an RGD sequence at position 366-368 within the third fibronectin-type II domain (41) . This site may serve as recognition motif for ␣v␤3. The RGD motif is absent in MMP-2 (42) . As proMMP-9 is secreted, its binding as a soluble ligand would likely require ␣v␤3 activation. This may explain why we found mature MMP-9 only in supernatants of breast cancer cells expressing activated ␣v␤3. Our cell model will be useful to test whether ␣v␤3 and its activation state are directly involved in MMP-9 processing.
The promigratory effect of mature MMP-9 was substrate specific and very pronounced in fibrinogen-directed migration. Fibrinogen is degraded by MMP-9 (20) (21) (22) . As a result, integrinmediated interaction may switch from support of firm adhesion to dynamic migration on the modified substrate (17) . Substrate processing by highly aggressive tumor cells can alter the response of less aggressive tumor cells in the vicinity (43) . Fibrinogen fragments released by MMP-9 may further attract breast cancer cells, as they are potent chemotaxins for neutrophils (44) . In addition, MMP-9 may exert a promigratory effect by modifying the functionality of breast cancer cell integrin ␣v␤3. Metal-loproteinases can promote tumor cell migration by modifying integrin subunits, thereby altering the activation state of the receptor (26, 45) . In our model, we preincubated nonactivated ␣v␤3-expressing breast cancer cells with MMP-9 or supernatants of cells bearing the activated receptor. This enhanced ␣v␤3-dependent migration. Thus, it is possible that the promigratory effect of MMP-9 was mediated through modification of the matrix as well as alterations of the cell surface.
Fibrinogen and fibrin are relevant matrices that disseminating breast cancer cells may encounter during metastasis. These proteins are found in primary tumor stroma, in the circulation, at sites of extravasation, and in the parenchyma of target organs where permeability factors cause fibrinogen leakage from the vasculature. A cascade of events, which begins with intrinsic activation of breast cancer cell integrin ␣v␤3, may therefore trigger a series of responses that lead to an increased propensity of tumor cells to interact with their matrices, arrest within the vasculature, and migrate toward specific substrates. Our study indicates that this can be potentiated by a positive feedback pathway where intrinsic activation of tumor cell ␣v␤3 upregulates metalloproteinase functionality, and this in turn enhances ␣v␤3 activity on neighboring tumor cells and converts matrix proteins into promigratory substrates.
